Table 2.
Clinical outcomes among patients who received tyrosine kinase inhibitors with CSF1R inhibition (N = 21)
| Characteristics | N | PFS | OS | |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| Median (months) (95% CI) | Univariate | Median (months) (95% CI) | Univariate | |||||
|
|
|
|||||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | |||||
| CSF1R (RNA expression rank) | < 50 | 7 | 4.04 (0-14.50) | Reference | - | 13.25 (CI not calculable) | Reference | - |
| ≥ 50-74 | 8 | 3.75 (1.61-5.89) | 1.6 (0.50-5.15) | 0.43 | 20.51 (0-42.69) | 0.71 (0.17-2.99) | 0.64 | |
| CSF1R (RNA expression rank) | < 50 | 7 | 4.04 (0-14.50) | Reference | - | 13.25 (CI not calculable) | Reference | - |
| ≥ 75 | 6 | 1.74 (0.95-2.53) | 3.79 (0.86-16.67) | 0.08 | 5.26 (0.69-9.83) | 2.06 (0.45-9.35) | 0.35 | |
| CSF1R (RNA expression rank) | < 50 | 7 | 4.04 (0-14.50) | Reference | - | 13.25 (CI not calculable) | Reference | - |
| ≥ 50 | 14 | 2.56 (0.27-4.85) | 1.93 (0.66-5.65) | 0.22 | 20.51 (0-53.77) | 0.58 (0.16-2.18) | 0.42 | |
| Gastrointestinal cancer | Yes | 7 | 3.91 (3.49-4.33) | Reference | - | 13.24 (4.14-22.35) | Reference | - |
| No | 14 | 3.35 (0-6.71) | 1.47 (0.53-4.04) | 0.45 | 20.51 (0-47.40) | 0.61 (0.19-1.94) | 0.40 | |
| Number of prior lines of therapy | ≥ 4 | 9 | 2.56 (1.22-3.91) | Reference | - | 22.52 (4.00-41.04) | Reference | - |
| < 4 | 12 | 4.04 (2.31-5.78) | 0.60 (0.22-1.62) | 0.31 | 20.51 (6.11-34.92) | 1.20 (0.38-3.79) | 0.75 | |
| Single agent therapy | Yes | 7 | 3.35 (0.79-5.92) | Reference | - | 22.52 (5.40-39.64) | Reference | - |
| No | 14 | 3.75 (1.28-6.22) | 0.71 (0.26-1.92) | 0.49 | 13.25 (0.15-26.34) | 2.51 (0.67-9.43) | 0.17 | |
Median progression-free survival (PFS) and overall survival (OS) were assessed. Univariate Cox regression analysis was performed for each variable to calculate hazard ratios (HR) with 95% confidence intervals (CI).